Fierce Biotech

Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio

Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...
Investor's Business Daily on MSN

Spyre Therapeutics flies on Takeda-rivaling ulcerative colitis results

Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis ...
Becker's ASC

Entyvio improves moderate-to-severe ulcerative colitis, Crohn’s

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Morningstar

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...
Healio

FDA approves subcutaneous Entyvio as maintenance therapy for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

Spyre stock soars as UC drug touts Entyvio-rivalling potential

Analysts are intrigued by SPY001’s early efficacy and dosing convenience, noting that the drug could compete with therapies ...
Nasdaq

Takeda Receives FDA Approval For Ulcerative Colitis Therapy

(RTTNews) - Takeda (TAK) said that the U.S. Food and Drug Administration has approved a subcutaneous or SC administration of Entyvio (vedolizumab) for maintenance therapy in adults with moderately to ...
Monthly Prescribing Reference

Entyvio for Subcutanous Administration Approved for Ulcerative Colitis

Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...

Spyre's inflammatory bowel drug shown to reduce disease activity in mid-stage study

By Siddhi Mahatole April 13 (Reuters) - Spyre Therapeutics said on Monday its experimental drug showed a significant reduction in disease activity when tested in patients with ulcerative colitis in a ...
The American Journal of Managed Care

Clinical and Economic Value of ENTYVIO® (vedolizumab): Implications for Ulcerative Colitis and Crohn Disease Management

This clinical brief was sponsored by Takeda Pharmaceuticals U.S.A., Inc,. This information is exclusively for Payer Formulary Committees or other similar entities (groups of individuals that evaluate ...
Nasdaq

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can ...

Spyre's inflammatory bowel drug reduces disease activity in mid-stage study

April 13 () - Spyre Therapeutics said on Monday its experimental drug demonstrated a significant reduction ‌in disease ...